Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2

The investigators carried out an analysis of the efficacy and safety of secukinumab (SEC) in the randomized placebocontrolled trials (RPCTs) FUTURE 1 and FUTURE 2, as well as a subanalysis of the data obtained in the Russian population of patients with active psoriatic arthritis (PsA). The FUTURE 1...

Descripció completa

Dades bibliogràfiques

Autors principals:	T. V. Korotaeva, E. G. Zotkin, O. B. Nesmeyanova, N. N. Vezikova, O. B. Ershova, N. V. Izmozzherova, M. S. Petrova, A. A. Kastanyan, S. P. Yakupova, A. S. Agafina, M. L. Stanislav, E. A. Novoderezhkina, E. L. Nasonov, P. J. Mease
Format:	Artigo
Idioma:	Russo
Publicat:	IMA PRESS LLC 2017-04-01
Col·lecció:	Научно-практическая ревматология
Matèries:	psoriatic arthritis secukinumab efficacy safety interleukin-17
Accés en línia:	https://rsp.mediar-press.net/rsp/article/view/3003
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!